New-age drug meets resistance

Nature. 2001 Jul 19;412(6844):281-2. doi: 10.1038/35085665.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Blast Crisis / genetics
  • Drug Approval
  • Drug Resistance, Neoplasm* / genetics
  • Enzyme Inhibitors / therapeutic use
  • Fusion Proteins, bcr-abl / drug effects
  • Fusion Proteins, bcr-abl / genetics*
  • Fusion Proteins, bcr-abl / physiology
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / physiopathology
  • Mutation
  • Piperazines / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Proto-Oncogene Proteins c-abl / genetics
  • Proto-Oncogene Proteins c-abl / metabolism
  • Pyrimidines / therapeutic use*
  • Recurrence
  • United States

Substances

  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • Proto-Oncogene Proteins c-abl